INmune Bio (NASDAQ:INMB) Issues Earnings Results

INmune Bio (NASDAQ:INMB) released its earnings results on Monday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is the company’s lead value driver and the team says it will file a U.K. MAA by mid‑summer 2026 (with subsequent EMA and U.S. BLA filings later in 2026), supported by reproducible batch manufacturing, defined potency assays/MOA, and clinical data showing wound healing, itch reduction, QoL improvements and a favorable safety profile.
• While management highlights encouraging biomarker and subgroup signals for XPro and an FDA alignment on a two‑stage adaptive Phase III, the MINDFuL Phase II did not meet its top‑line primary endpoint (leading to a $16.5M intangible‑asset impairment) and the program will require additional partner funding to advance.
• The company reported $24.8M in cash at year‑end 2025 and believes this funds operations only through Q1 2027, implying near‑term financing or partnership needs given ongoing development plans and a net loss of $45.9M for 2025.
• INKmune’s Phase II in metastatic castration‑resistant prostate cancer was completed ahead of schedule and under budget, meeting its primary endpoint and two of three secondary endpoints, which management positions as de‑risking that program.

INmune Bio Price Performance

NASDAQ:INMB opened at $1.18 on Wednesday. The company’s 50-day moving average is $1.39 and its two-hundred day moving average is $1.64. The firm has a market capitalization of $31.36 million, a price-to-earnings ratio of -0.63 and a beta of 0.77. INmune Bio has a 1-year low of $1.09 and a 1-year high of $11.64.

Analyst Ratings Changes

A number of research firms have weighed in on INMB. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds have recently modified their holdings of INMB. Intech Investment Management LLC purchased a new position in shares of INmune Bio during the 2nd quarter worth approximately $26,000. Squarepoint Ops LLC acquired a new stake in shares of INmune Bio in the third quarter valued at $30,000. Quadrature Capital Ltd purchased a new stake in shares of INmune Bio in the 4th quarter valued at $26,000. Jane Street Group LLC acquired a new position in INmune Bio during the 1st quarter worth about $142,000. Finally, Rhumbline Advisers lifted its stake in INmune Bio by 14.4% during the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after acquiring an additional 2,409 shares in the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.